Switch theme
Sign up to access all valuation multiples
Mesa Laboratories Inc manufactures life sciences tools and critical quality control products. It operates in 4 divisions: Sterilization and Disinfection Control, which manufactures and sells biological, chemical, and cleaning indicators used to assess the effectiveness of sterilization, decontamination, disinfection, and cleaning processes. Clinical Genomics division develops, manufactures, and sells highly sensitive, low-cost, high-throughput genetic analysis tools and related consumables. The Biopharmaceutical Development division develops, manufactures, and sells automated systems for protein analysis (immunoassays) and peptide synthesis solutions. The Calibration Solutions division develops, manufactures, sells, and services quality control products.
1982
736
LTM Revenue $241M
LTM EBITDA $59.7M
$801M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Mesa Laboratories has a last 12-month revenue of $241M and a last 12-month EBITDA of $59.7M.
In the most recent fiscal year, Mesa Laboratories achieved revenue of $216M and an EBITDA of -$238M.
Mesa Laboratories expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Mesa Laboratories valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $219M | $216M | XXX | XXX | XXX |
| Gross Profit | $109M | $134M | XXX | XXX | XXX |
| Gross Margin | 50% | 62% | XXX | XXX | XXX |
| EBITDA | $38.2M | -$238M | XXX | XXX | XXX |
| EBITDA Margin | 17% | -110% | XXX | XXX | XXX |
| Net Profit | $1.9M | $0.9M | XXX | XXX | XXX |
| Net Margin | 1% | 0% | XXX | XXX | XXX |
| Net Debt | $169M | $150M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, Mesa Laboratories's stock price is $114.
Mesa Laboratories has current market cap of $620M, and EV of $801M.
See Mesa Laboratories trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $801M | $620M | XXX | XXX | XXX | XXX | $7.98 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, Mesa Laboratories has market cap of $620M and EV of $801M.
Mesa Laboratories's trades at 3.3x LTM EV/Revenue multiple, and 13.4x LTM EBITDA.
Analysts estimate Mesa Laboratories's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Mesa Laboratories and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $801M | XXX | XXX | XXX |
| EV/Revenue | 3.4x | XXX | XXX | XXX |
| EV/EBITDA | -53.8x | XXX | XXX | XXX |
| P/E | -10.8x | XXX | XXX | XXX |
| P/E/Growth | n/a | XXX | XXX | XXX |
| EV/FCF | 20.4x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpMesa Laboratories's NTM/LTM revenue growth is 5%
Mesa Laboratories's revenue per employee for the last fiscal year averaged $0.3M, while opex per employee averaged $0.2M for the same period.
Over next 12 months, Mesa Laboratories's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Mesa Laboratories's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Mesa Laboratories and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | -1% | XXX | XXX | XXX | XXX |
| EBITDA Margin | -6% | XXX | XXX | XXX | XXX |
| EBITDA Growth | -724% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | -2% | XXX | XXX | XXX | XXX |
| Revenue per Employee | $0.3M | XXX | XXX | XXX | XXX |
| Opex per Employee | $0.2M | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | 18% | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | 34% | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | 9% | XXX | XXX | XXX | XXX |
| Opex to Revenue | 60% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Philips | XXX | XXX | XXX | XXX | XXX | XXX |
| Perspective Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| SmartVest | XXX | XXX | XXX | XXX | XXX | XXX |
| InfuSystem | XXX | XXX | XXX | XXX | XXX | XXX |
| Myomo | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Mesa Laboratories acquired XXX companies to date.
Last acquisition by Mesa Laboratories was XXXXXXXX, XXXXX XXXXX XXXXXX . Mesa Laboratories acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Mesa Laboratories founded? | Mesa Laboratories was founded in 1982. |
| Where is Mesa Laboratories headquartered? | Mesa Laboratories is headquartered in United States of America. |
| How many employees does Mesa Laboratories have? | As of today, Mesa Laboratories has 736 employees. |
| Who is the CEO of Mesa Laboratories? | Mesa Laboratories's CEO is Mr. Gary M. Owens. |
| Is Mesa Laboratories publicy listed? | Yes, Mesa Laboratories is a public company listed on NAS. |
| What is the stock symbol of Mesa Laboratories? | Mesa Laboratories trades under MLAB ticker. |
| When did Mesa Laboratories go public? | Mesa Laboratories went public in 1995. |
| Who are competitors of Mesa Laboratories? | Similar companies to Mesa Laboratories include e.g. Philips, Perspective Therapeutics, SmartVest, InfuSystem. |
| What is the current market cap of Mesa Laboratories? | Mesa Laboratories's current market cap is $620M |
| What is the current revenue of Mesa Laboratories? | Mesa Laboratories's last 12-month revenue is $241M. |
| What is the current EBITDA of Mesa Laboratories? | Mesa Laboratories's last 12-month EBITDA is $59.7M. |
| What is the current EV/Revenue multiple of Mesa Laboratories? | Current revenue multiple of Mesa Laboratories is 3.3x. |
| What is the current EV/EBITDA multiple of Mesa Laboratories? | Current EBITDA multiple of Mesa Laboratories is 13.4x. |
| What is the current revenue growth of Mesa Laboratories? | Mesa Laboratories revenue growth between 2023 and 2024 was -1%. |
| Is Mesa Laboratories profitable? | Yes, Mesa Laboratories is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
